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Upregulation of LAT1 during anti-androgen therapy contribute to progression in 
prostate cancer cells  
 
Abstract  
Purpose  
Cancer cells require massive amounts of amino acids for survival. L-type amino acid 
transporter 1 (LAT1) transports essential amino acids, including leucine, which trigger 
the downstream m-TOR pathway. The association between androgen receptor (AR) and 
LAT1 and the association between LAT1 expression and acquisition of castration 
resistance were examined.  
 
Materials and Methods 
Western blotting and real-time polymerase chain reaction were used to study protein and 
mRNA expressions. SiRNA was used to knockdown target genes. 92 prostate biopsies 
specimen of patients who underwent androgen deprivation therapy (ADT) were used for 
immunohistochemical analyses. Cox hazard proportional models and the Kaplan-Meier 
method were used for statistical analyses. 
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Results  
LAT1 was highly expressed in hormone-resistant prostate cancer cell lines. Knockdown 
of LAT1 in LNCaP and C4-2 cells significantly suppressed cell proliferation, migration, 
and invasion. SiRNA of AR or blocking of AR through bicalutamide (10µΜ) or 
MDV3100 (10µΜ) significantly increased LAT1 expression (P<0.01). Treatment with 
DHT (0.1-10 nM) reduced LAT1 expression in a dose-dependent manner (P<0.01). 
Bicalutamide/MDV3100 plus SiLAT1synergistically suppressed prostate cancer cell 
proliferation compared to single inhibition of AR or LAT1 (P<0.01). The high LAT1 
expression correlated with significantly shorter PSA recurrence free survival in patients 
receiving ADT (P<0.0001). LAT1 expression (HR 3.56, P = 0.0133) was an independent 
predictor of castration resistance on multivariate analysis.  
 
Conclusions  
The current data may provide a novel mechanism to acquire castration resistance 
through activation of amino acid transporter LAT1.  
 
Introduction 
Prostate cancer (PC) is one of the most commonly diagnosed cancers in men.(1, 2) 
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Since the historical discovery of Dr. Huggins, androgen deprivation therapy (ADT) has 
been the mainstay of therapy for locally advanced or metastatic PC.(3) Despite the early 
response to ADT, the majority of patients with advanced disease progress and become 
refractory to ADT due to emergence of androgen-independent PC cells.(2, 4-6) 
Although several mechanisms have been proposed, the androgen receptor (AR) plays a 
central role in the development of CRPC through genomic amplification, ligand 
independent activation, ETS Related Gene (ERG) fusion, and splicing variants.(7-10)  
Cancer cells take up massive amounts of amino acids for survival. L-type amino acid 
transporter 1 (LAT1) is a member of the solute carrier (SLC) family and transports 
neutral amino acids, including essential amino acids, into cells in a Na+-independent 
manner.(11) A high level of LAT1 expression has been observed in a wide variety of 
malignant cells, while normal cells showed limited expression of LAT1, with the only 
expression reported in the vascular endothelial cells of the blood-brain barrier and 
syncytiotrophoblastic cells of the placenta.(11) Therefore, it has been suggested that 
LAT1 plays an essential role in malignant tumor growth by promoting uptake of 
essential amino acids. Recent evidence has also suggested that LAT1 regulates 
mammalian target of rapamycin complex 1 (mTORC1), which requires intracellular 
amino acids such as leucine for its activity.(12) However, the role of LAT1 in the 
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androgen receptor-mediated pathway remains to be investigated.  
In this study, we investigated the regulation of LAT1 by androgen receptor and 
studied functional contribution of LAT1 in castration resistant prostate cancer.  
 
Materials and Methods 
Reagents and antibodies 
Lipofectamine RNAiMax reagent,siLAT1 (Stealth siRNAs HSS112004, HSS112005, 
HSS188571), siAR (Stealth siRNAs, HSS100619, HSS179972, HSS179973), and 
Stealth RNAi siRNA Negative Control Med GC Duplex #3were purchased from 
Invitrogen (Burlington, ON, Canada). Anti-LAT1 (Trans Genic Inc.; KE023), and 
anti-AR (AR441, ab9474) were obtained from Abcam (Cambridge, UK). 
Anti-phosphorylated AKT (Ser473) (587F11), anti-Phospho-4E-BP1 (Thr37/46) 
(236B4), and anti-Phospho-p70 S6 Kinase (Thr389) (108D2) were obtained from Cell 
Signaling Technology (Danvers, MA, USA). Anti-GAPDH was purchased from 
Applied Biosystems (Foster, CA, USA). 
 
PC tissue specimens  
Total of 92 PC tissue specimens (92 biopsy specimens subsequently treated with 
anti-androgen therapy) obtained at Chiba University hospital were used for the analysis. 
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Histopathologic analysis of the tissues was performed according to the World Health 
Organization criteria by the Department of Pathology, Chiba University Hospital. All 
patients had PC that was histologically confirmed, and tumor samples were checked to 
ensure that tumor tissue was present in the specimen. 
 
Cell culture and transfection  
LNCaP, C4-2, PC3, and DU145 cell lines, derived from human PCs, were obtained 
from the RIKEN BRC CELL BANK (Tsukuba, Ibaragi, Japan). The PC cell lines were 
cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 
maintained in an incubator with a humidified atmosphere of 95% air and 5% CO2 at 
37 °C. For steroid-free conditions, phenol red-free RPMI-1640 medium was used with 
charcoal-stripped FBS (CS-FBS). PC cells were transfected with DNA and/or siRNA 
using Lipofectamine 2000 and/or Lipofectamine RNAiMax reagent (Invitrogen), 
according to the manufacturer’s instructions.  
 
Evaluation of mRNA expression 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands) 
according to the manufacturer’s instructions. First-strand complementary DNA (cDNA) 
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was synthesized using the ImProm-II™ Reverse Transcription System with random 
primers (Promega, Tokyo, Japan). Real-time RT-PCR was performed using an ABI™ 
7300 Real-Time PCR System. PCR reactions were performed in a final volume of 25 μl 
of a reaction mixture of SYBR® Green PCR Master Mix. Primer sequences used for 
PCR amplification were: LAT-1 Forward: AGGAGCCTTCCTTTCTCCTG, LAT-1 
Reverse: CTGCAAACCCTAAGGCAGAG, AR Forward: 
CCTGGCTTCCGCAACTTACAC, AR Reverse: GGACTTGTGCATGCGGTACTCA. 
Relative mRNA expression levels were determined by comparison to the GAPDH 
internal control and plotted as a ratio to GAPDH expression values. 
 
Western blot analysis 
Protein expression was determined by immunoblotting using the specific antibodies 
mentioned above. Protein levels were normalized to GAPDH expression. The 
experiments were performed according to the protocol described previously.(13) 
Signal detection was achieved with the ECL Prime Western Blotting Detection Reagent 
(GE Healthcare Bio-Sciences, Princeton, NJ) and visualized using LAS-4000 mini 
(FUJIFILM, Tokyo, Japan).  
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Immunohistochemistry (IHC) was performed on 4-μm-thick sections of 
paraffin-embedded specimens using goat anti-LAT1 polyclonal antibody according to 
the protocol described previously.(13) To quantify the state of LAT1 protein expression 
in these components, each mean percentage of LAT1-positive tumor cells was 
determined in at least five random fields at ×400 magnification in each section. The 
intensity of the LAT1 immunoreaction was scored as follows: 0, no staining; 1+, very 
weak; 2+, moderate; 3+, strong; and 4+, very strong. The staining intensity was scored 
to produce each LAT1 IHC score. Pathological evaluations were performed under 
consultation of pathologist Jun Matsushima. These judgments were made by two 
independent investigators (S.S. and X. M.) both of whom were blinded to the patients’ 
clinical status. 
 
Growth assay 
Cells were trypsinized, and equal numbers (4×103 cells) were seeded in a 96-well 
culture plate for all transfection conditions. After 24 h, the media were changed for 
fresh complete media (10% FBS), and all sets of cells were transfected with siRNA 
using Lipofectamine RNAiMax reagent (Invitrogen), according to the manufacturer’s 
instructions, and left for 4 days. At each indicated time point, cells were trypsinized and 
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counted. 
 
Patient selection and clinical variables 
92 biopsy specimens from patients who underwent CAB (combined androgen blockade) 
as first-line therapy for PC at Chiba University Hospital were retrospectively analyzed. 
The prognostic values of LAT1 expression and other clinical factors were evaluated in 
association with prostate specific antigen (PSA) progression-free survival.PSA failure 
was defined according to the definition of The Prostate Cancer Clinical Trials Working 
Group 2 (PCWG2): a rising PSA greater than 2 ng/mL higher than the nadir; the rise 
has to be at least 25% over the nadir; and the rise has to be confirmed by a second PSA 
at least three weeks later. 
 
Ethical approval 
Study was approved by institutional review board (IRB) # 408 and written informed 
consents were obtained from the patients. 
 
Statistical analysis 
Univariate and multivariate Cox proportional models and the Kaplan-Meier method 
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were used for statistical analyses. Student’s t-test, the chi-square test, and Wilcoxon’s 
signed rank test were used to assess the associations of LAT1 expression and other 
clinical variables. Statistical computations were carried out using JMP 11.0.0 (SAS 
Institute, Cary, NC, USA). Significance was set at P< 0.05.  
 
Results 
The expression of LAT1 in PC tissues and the correlation between LAT1 and clinical 
variables  
Protein expression of LAT1 was examined in PC patients by immunohistochemistry 
(IHC) of prostate specimens. Representative IHC results of biopsy specimen for LAT1 
protein in normal prostate tissue and PC tissue are shown in Figure1. A positive 
immunoreaction for LAT1 was detected in the membrane, together with the cytoplasm. 
Strong LAT1 immunoreactions were detected in cancer lesions (black arrow head), 
whereas noncancerous lesions showed negative or weak immunostaining (white arrow 
head) (Figure 1A, B). LAT1 expression tends to increase from gleason score (GS) 3 to 5 
(Figure 1C, D). Although negative correlation of AR and LAT1 were observed in some 
lesion, no clear trends between LAT1 and AR (nor PSA) were observed overall 
(Supplementary figure 1-3).  
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Next, protein expression levels of LAT1 in biopsy specimen of patients who underwent 
ADT were studied. Specimens were divided into two groups based on LAT1 and 
nucleus AR staining (median intensity score (IS) of 3). In biopsy specimens of ADT 
patients, high LAT1 expression showed significantly shorter time to CRPC than those 
with low LAT1 expression (P<0.0001) (Figure 2A). Although high AR expression 
group tend to show short time to CRPC, AR expression did not correlated with PSA 
recurrence free survival (P=0.0591) (Figure 2B). When combined LAT1 and AR 
expression, high AR/ high LAT1 group showed the worst PSA recurrence free survival, 
followed by high LAT1/ low AR group. High AR/ Low LAT1 and Low AR/ Low 
LAT1 groups showed similar favorable prognosis (Figure 2C).  
 
Evaluation of LAT1 protein expression in PC-derived cell lines 
To investigate basal protein expression of LAT1, Western blot analysis was performed 
using three PC-derived cell lines (LNCaP, C4-2, PC-3,DU145) (Figure 3A). A 
significant increase in LAT1 protein expression was observed in androgen-independent 
C4-2 cells compared to androgen-sensitive LNCaP cells. LAT1 was highly expressed in 
other androgen-independent AR-negative PC-3 and DU145 cells. Expression analysis 
indicated that both transcription and translation products of this molecule were highly 
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expressed in androgen-independent cell lines (Figure 3B). 
 
Establishment of LAT1 knockdown cells 
To obtain transient LAT1 knockdown transfectants, the LAT1 siRNA (siLAT1#1-2) 
plasmid and the negative control siRNA (Nega) plasmid were used. LAT1 mRNA and 
protein expression was significantly lower (<80%) in siLAT1-transfected cells than in 
Negative-transfected cells in C4-2 cells and LNCaP Cells (Figure 3C, D, E and F).  
 
LAT1 knockdown inhibited cell growth, migration, and invasion  
To investigate the anti-proliferative effects in siLAT1-transfected cells, cellular growth 
was monitored for 4 days. The siLAT1-transfected cells showed a significant decrease 
in cellular growth compared with Nega-transfected cells in LNCaP cells and C4-2 cells 
(Figure 4A and B). SiLAT1-transfected cells also showed significant decreases in 
cellular migration and invasion compared with Nega-transfected cells in LNCaP and 
C4-2 cells (Figure 4C, D, E and F).  
 
LAT1 knockdown inhibited m-TOR pathway  
In order to investigate the effect of LAT1 knockdown on the m-TOR pathway, siLAT1 
were transfected in C4-2 cells, and the phosphorylation status of downstream 
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m-TOR-related proteins was studied. SiLAT1 inhibited phosphorylation of ribosomal 
protein S6 kinase 1 (S6K1) and Eukaryotic translation initiation factor 4E-binding 
protein 1 (4EBP1) (lane 72h), while phosphorylation of AKT was not affected by 
siLAT1 (Figure 5A).  
 
AR knockdown increased LAT1 expression  
In order to study the association of AR and LAT1, siAR were transfected in LNCaP and 
C4-2 cells. Knockdown of AR significantly increased protein and m-RNA levels of 
LAT1 in LNCaP and C4-2 cells (Figure 5B and C).  
 
Bicalutamide and MDV3100 increased LAT1 expression in the presence of 
dihydrotestosterone (DHT)  
Next, the effect of DHT on LAT1 expression was examined. DHT decreased expression 
of LAT1 in a dose-dependent manner (DHT 0 to 10nM), while bicalutamide increased 
LAT1 expression (protein and mRNA levels), even in the presence of DHT (Figure 5D). 
The effects of anti-androgens to increase LAT1 expression were similar for 
bicalutamide and MDV3100 (Figure 5E) compared to DHT-only treated cells. LAT1 
expression was also assessed in the serum-free condition (5% charcoal filtered FBS), 
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resembling the castrated condition, and LAT1 expression increased in a time-dependent 
manner (24 hours to 7 days), along with time-dependent decreased expression of AR 
(Figure 5F).  
 
Knockdown of AR and LAT1 significantly inhibited cellular growth in LNCaP and 
C4-2 cells  
Since blocking of AR increased LAT1 expression, the effect of dual inhibition of AR 
and LAT1 using bicalutamide and MDV3100 in combination with siLAT1 was studied 
in LNCaP and C4-2 cells (Figure 6). The inhibitory effect of cellular growth mediated 
by bicalutamide or MDV3100 was similar to that of LAT1 knockdown in both LNCaP 
and C4-2 cells. Dual inhibition of AR (through bicalutamide or MDV3100) and LAT1 
significantly inhibited cellular growth compared to single inhibition by AR or LAT1. 
Interestingly enough, cells treated with anti-androgen and siLAT1 almost completely 
lost their ability to promote cellular growth (Figure 6A-D) in both LNCaP and C4-2 
cells. 
 
In order to study the clinical factors associated with LAT1 expression, high and low 
LAT1 groups were compared (Table 1). High LAT1 correlated with higher ALP 
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(P=0.023), PSAD (P=0.03), PSA nadir (P=0.048), cT stage (P=0.0001), and GS 
(P<0.0001). High LAT1 also correlated with lower age (P=0.001), shorter PSA and TST 
time to nadir (P=0.003 and P=0.001, respectively) (Table 1).  
Furthermore, when assessing the risk of PSA recurrence, on multivariate analysis, 
LAT1 expression remained as a significant prognostic factor for PSA recurrence under 
ADT (HR 3.56; P = 0.013), together with GS (HR 1.98; P=0.042) (Table 2). 
 
Discussion 
The current data indicated upregulation of LAT1 under castrated condition in PC cells. 
Knock down of AR or treatment with anti-androgens, such as bicalutamide or 
MDV3100, showed increased LAT1 expression, while treatment with DHT reduced 
LAT1 expression. Overexpression of LAT1 in patients with ADT was associated with 
significantly shorter time to CRPC. These data indicate the contribution of the amino 
acid transporter LAT1 in the adaptation under castrated condition in PC cells. Since 
blocking AR increased LAT1 expression, dual inhibition of LAT1 and AR may have 
therapeutic significance in CRPC patients.  
At this stage, the mechanism for the negative regulation of LAT1 by androgen 
receptor signals is not still clear, whether it is a direct interaction of the androgen 
receptor with LAT1 or indirect regulation through bypassing signals. Wang et al. 
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reported that LAT1 is regulated by the amino acid stress pathway and activating 
transcription factor4 (ATF4) mediated transcription.(14). They demonstrated 
upregulation of ATF4 under the leucine-free condition, which stimulated transcription of 
LAT1 in AR-positive LNCaP cells and AR-negative PC-3 cells. In the present analysis, 
blocking AR significantly increased LAT1 expression with leucine-containing normal 
medium, in AR specific manner, indicating current mechanism is distinct from the 
ATF4-mediated pathway. Classically, direct interaction of AR is known in PTEN and 
Fork-head box protein A1 (FOXA1). (13, 15, 16) FOXA1 supports AR function by 
opening up chromatin, and thus SiRNA of FOXA1 caused a significant reduction of AR 
activation.(13) In the case of LAT1, knockdown of LAT1 did not have any effect on AR 
expression or activation. The only expression change in LAT1 occurred when AR was 
knocked down or blocked by anti-androgen. Thus, LAT1 seems to be a downstream 
signal of AR, but direct interaction or mutual regulations are to be determined.  
In the current study, high LAT1 expression was an independent risk factor for PSA 
recurrence during ADT. High LAT1 expression was related to high GS, cT stage, PSAD, 
PSA nadir and short time to nadir for PSA/Testosterone (TST). The correlation between 
LAT1 and GS was in accordance with the previous report by Segawa et al.(17) 
Regarding time to PSA or TST nadir, our group reported that patients with high nadir 
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TST or PSA require a shorter time to reach nadir than low nadir patients, which 
correlated with poor prognosis(18). In the current results as well, high LAT1 patients 
showed higher nadir PSA (P=0.048) and relatively higher nadir TST (P=0.088), that 
may affect the prognosis of the ADT patients.  
In relation with AR and amino acid transporter, Wang et al., reported positive 
regulation of LAT3 by AR in prostate cancer cells. They indicated neoadjuvant 
hormonal therapy significantly decreased LAT3 expression. In combination with our 
data, one of the possible mechanisms may be that hormonal therapy decrease LAT3, 
while increase LAT1 during adaptation in castrated condition to acquire essential amino 
acids into PC cells (19).  
Another reason for early recurrence in high LAT1 patients may be the contribution of 
AR-independent survival signals including the m-TOR pathway. In the present data, in 
accordance with previous reports (14, 20, 21), knockdown of LAT1 inhibited 
downregulation of the mTORC1 pathway through inhibition of phosphorylation of 
S6K1 and 4EBP1. 
These mechanisms may contribute not only to hormone naïve prostate cancer treated 
with first-line ADT, but also for CRPC patients receiving MDV 3100 or abiraterone, 
which significantly block the AR/TST-mediated pathway. The presence of association 
17 
 
between LAT1 expression and resistance to novel AR targeted drugs will be analyzed 
further in the future.  
 As limitations, overexpression of LAT1 was first tried in order to study the functional 
significance of LAT1. However, no remarkable functional difference was seen 
(Supplementary figure 4A), which was in accordance with a previous report that only 
used SiRNA, ShRNA, or LAT1 inhibitor BCH, but not an overexpression system.(14, 
22, 23) Second, the precise mechanism of how AR negatively regulates LAT1 is not still 
clear. Effect of LAT1 knock down seems to be more prominent in AR positive cells 
compare to AR negative cells (Supplementary figure 4 B, C). We are currently pursuing 
co-immunoprecipitation and a chip assay to determine the possibility of direct 
interaction between LAT1 and AR. It is not still clear whether AR directly regulate 
LAT1 expression or as a result of adaption of PC cells under blockade of AR mediated 
pathway. Third, no significant negative correlation between LAT1 and AR were 
observed in clinical specimens. This may represent presence of multiple regulatory 
pathways of LAT1 in microenvironment including ATF4 and c-MYC (14, 24). Fourth, 
the study cohort used for determination of LAT1 and clinical factors was small, and the 
study was retrospective. A large, prospective study will clarify the precise contribution 
of LAT1 in predicting the prognosis of PC patients undergoing ADT. We are currently 
18 
 
planning a prospective study assessing expressional differences of LAT1 before and 
after treatment with MDV3100 and Abiraterone.  
 
Conclusion 
The current study found negative regulation of amino acid transporter LAT1 through 
AR. Increased expression of LAT1 under androgen deprivation therapy may potentially 
contribute to acquisition of castration resistance in PC cells. Since targeting only AR 
mediated pathway has limited efficacy especially after development of CRPC, dual 
inhibition of AR plus LAT1 may give us another opportunity to control CPRC 
progression. Future direction will be to study the association between LAT1 expression 
and acquisition of abiraterone and MDV3100 resistance in CPRC patients.  
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Figure Legends 
Figure1. LAT1 expression in prostate cancer biopsy specimens   
Representative immunohistochemical expressions of LAT1 in Gleason pattern 4 (black 
arrow head) and benign gland (white arrow head) are shown in low magnification (x20) 
(Figure A) and high magnification (x200) (Figure B). Gleason pattern 3 to 5 are shown 
in low magnification (x20) (Figure C) and Gleason pattern 3(black arrow head) and 
Gleason pattern 4(white arrow head) are shown in high magnification(x200) (Figure D).  
 
Figure 2.  
Kaplan-Meier analysis of PSA recurrence free survival related to LAT1 and AR 
expression in ADT patients. Figure A represents PSA recurrence free survival of 
prostate cancer patients underwent androgen deprivation therapy in LAT1 high and Low 
patients. Figure B represents PSA recurrence free survival of prostate cancer patients 
underwent androgen deprivation therapy in AR high and Low patients. Figure C 
represents PSA recurrence free survival of prostate cancer patients underwent androgen 
deprivation therapy stratified by LAT1 and AR expression. (*: P<0.05, **: P<0.01, ***: 
P<0.001) 
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Figure 3. Expression of LAT1 in prostate cancer cells  
Protein (A) and m-RNA (B) levels of LAT1 were examined in prostate cancer cells, 
include LNCaP, C4-2, PC3, and DU145 cells. SiRNA of LAT1 (#1 and #2) significantly 
knocks down LAT1 expression in LNCaP (C and D) and C4-2 cells (E and F). Data are 
representative of three separate experiments. (**: P<0.01) 
 
Figure 4. Functional significance of LAT1 in LNCaP and C4-2 cells  
SiLAT1 inhibits cell proliferation (A, B), cell migration (C, D), and cell invasion (E, F) 
in LNCaP and C4-2 cells. Data are representative of three separate experiments. (*: 
P<0.05, **: P<0.01, ***: P<0.001)  
 
Figure 5. Role of LAT1 in the m-TOR and AR-related pathways  
Knock down of LAT1 protein inhibits phosphorylation of p70S6K and 4EBP-1, but not 
AKT (72 h) (A). SiAR increases LAT1 expression in LNCaP and C4-2 cells (protein 
level (B) and mRNA level (C)). DHT inhibits LAT1 expression, but adding 
anti-androgen (bicalutamide) increases LAT1 expression (D). Adding DHT to 
5%-charcoal filtered FCS decreases LAT1 expression, while adding bicalutamide 
(10µM) or MDV3100 (10µM) reverses the effect of DHT (E). AR expression decreases 
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time dependently, while LAT1 increases time dependently with 5% charcoal filtered 
FCS (F). Data are representative of three separate experiments. (*: P<0.05, **: P<0.01) 
 
Figure 6. Effect of dual inhibition of LAT1 and AR pathways in cell proliferation 
Cell proliferation was examined in control, bicalutamide (10µM), SiLAT1, and 
SiLAT1+bicalutamide (10µM) at day 1 (24 h) to day 3 (72 h) in C4-2 cells (A) and 
LNCaP cells (B). Cell proliferation was also examined in control, MDV3100 (10 µM), 
SiLAT1, and SiLAT1+MDV3100 (10µM) at day 1 (24 h) to day 3 (72 h) in C4-2 cells 
(C) and LNCaP cells (D). Data are representative of three separate experiments. (*: 
P<0.05, **: P<0.01)  
 
Supplementary figure 1. 
Expression of LAT1 (A), AR (B) and PSA (C) in serial biopsy specimen.   
PSA, along with AR and LAT1 expressions were higher in cancer lesion (black arrow 
head) compare to benign lesion (white arrow head).  
 
Supplementary figure 2.  
Expression of LAT1 (A), AR (B) and PSA (C) in serial biopsy specimen (Gleason 3 to 
26 
 
5). AR and LAT1 expressions were higher in Gleason 3 (black arrow head), 4 (white 
arrow head) and 5 lesion, however, PSA showed weak or no staining at same lesion.  
 
Supplementary figure 3. 
Negative correlation of AR and LAT1 staining in specific lesion.  
LAT1 staining is low (B) in AR staining high lesion (A), while LAT1 staining is high 
(D) in AR staining low (C) lesion.  
 
Supplementary figure 4. 
LAT1 and cell proliferation 
Overexpression of LAT1 in LNCaP cells showed only slight increase but no significant 
increase in cell proliferation (P=0.33) (A).  
Knock down of LAT1 in DU145 (B) and PC3 (C) cells showed no remarkable 
difference in cell proliferation (P>0.05).  
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Key of Definitions for Abbreviations (only include abbreviations used 3 times or more in manuscript) 
 
 
Key of Definitions for Abbreviations 
 
 
 
ADT: Androgen deprivation therapy 
CRPC: Castration resistant prostate cancer 
PSA: Prostate specific antigen 
LAT1: Human L-type amino acid transporter 1 
AR: Androgen receptor 
DHT: Dihydrotestosterone 
TST: Testosterone 
 
 
Table 2 Risk of PSA recurrence in patients undergoing androgen deprivation therapy 
    Univariate Analysis Multivariate Analysis 
Clinical Factor Cut off HR Confidence interval P-value HR 
Confidence 
interval P-value 
Age  72 0.68 0.37-1.25 0.2155       
BMI  23.9 0.54 0.29-1.01 0.0537       
cT stage  3 4 1.99-8.92 <.0001 1.79 0.74-4.8 0.208  
GS  9 8.07 3.77-19.96 <.0001 1.98 1.03-3.95 0.042  
ALP  240 2.16 1.17-4.15 0.0135 1.49 0.79-2.94 0.220  
PSA  41.36 5 2.43-11.63 <.0001 1.63 0.57-4.85 0.366  
LAT1  H/L 6.38 2.56-21.31 <.0001 3.56 1.28-12.68 0.013  
AR H/L 1.91 0.99-3.97 0.0537       
BMI: body mass index(kg/m2); cT stage: Clinical T stage; GS: gleason score; ALP: alkaline phosphatase 
(ng/dL); PSA: prostate specific antigen; LAT1: L-type amino acid transporter 1; AR: androgen receptor . 
Table1 Clinical factors associated with LAT1 expression in ADT patients  
LAT1 Low High   
  Average SD Average SD P 
Age 74.96  1.31  69.64  0.85  0.001  
BMI 25.01  0.70  24.13  0.43  0.283  
ALP 226.78  70.88  423.00  46.04  0.023  
PSA  42.72  209.05  509.65  135.78  0.064  
PSAD 0.84  3.42  9.71  2.14  0.030  
PSA nadir  0.23  1.23  3.18  0.81  0.048  
TST  5.77  0.53  5.05  0.39  0.284  
TST nadir  0.12  0.02  0.15  0.01  0.088  
PSA TT nadir  20.24  2.49  11.25  1.64  0.003  
TST TT nadir  36.41  4.65  16.22  3.35  0.001  
cT stage (≥3) 29.63%   73.33%   0.0001  
Gleason Score (≥9) 3.70%   51.56%   <.0001 
AR Score 2.37  0.22  2.80  0.15  0.114  
BMI: body mass index(kg/m2);  ALP: alkaline phosphatase (ng/dL);  PSA: prostate specific antigen; 
PSAD: PSA density;  TST: testosterone(ng /dL );  TT nadir: time to nadir(month);  cT stage: Clinical T stage ; 
AR Score: Androgen receptor staining score. 
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